EGFR and non-small cell lung carcinoma: The US Food and Drug Administration (FDA) has already approved a ctDNA test involving monitoring EGFR (epidermal growth factor receptor) mutations in the serum of non-small cell lung cancer patients to determine eligibility for the chemotherapy drug erlotinib [7], and another test to determine ctDNA residue after surgery has been granted breakthrough device status [8].